Mesoblast
MESO
26 hedge funds and large institutions have $5.48M invested in Mesoblast in 2024 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 14 closing their positions.
158% more capital inflows, than outflows
Capital inflows: $1.24M | Capital outflows: $481K
149% more call options, than puts
Call options by funds: $1.6M | Put options by funds: $641K
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
0.22% more ownership
Funds ownership: 0.85% → 1.07% (+0.22%)
16% less funds holding
Funds holding: 31 → 26 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SX
Summit X
Chesterfield,
Missouri
|
+$265K |
| 2 |
Regal Partners
Sydney, NSW,
Australia
|
+$250K |
| 3 |
PWM
Prosperity Wealth Management
San Ramon,
California
|
+$165K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$134K |
| 5 |
Chase Investment Counsel
Charlottesville,
Virginia
|
+$127K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$184K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$118K |
| 3 |
Lattice Capital Management
Kirkland,
Washington
|
-$33.1K |
| 4 |
Rathbones Group
Liverpool,
United Kingdom
|
-$26.9K |
| 5 |
Penbrook Management
New York
|
-$26.6K |
MESO Hedge Fund Activity: Q1 2024 in Review
26 of the 6,968 institutional investors tracked by Wall St. Rank reported a position in Mesoblast (MESO) for Q1 2024, worth a combined $5.48M — up 244% from $1.59M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of MESO and 9 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 10 added.
The largest buyer was Summit X, adding an estimated $265K. The largest seller was Morgan Stanley, cutting an estimated $184K.
- 26 institutional investors held Mesoblast (MESO) as of Q1 2024, down from 31 in Q4 2023.
- Funds reported $5.48M of Mesoblast stock for Q1 2024, up 244% quarter-over-quarter.
- 9 funds opened new Mesoblast positions in Q1 2024 and 14 closed out, a net change of -5 holders.
- The largest Mesoblast buyer in Q1 2024 was Summit X, an estimated $265K added.
- The largest Mesoblast seller in Q1 2024 was Morgan Stanley, an estimated $184K sold.
Based on aggregated 13F filings for Q1 2024.